Concepedia

Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration

Alessandro Mariani, A. Deli, Aude Ambresin, Irmela Mantel

Graefe s Archive for Clinical and Experimental Ophthalmology · 2011 · 40 citations · 25 references

DOIFull text

Open access

Concepts

References

25

Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.9K citations · Full text

, , +12

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

David M. Brown, Peter K. Kaiser, Mark Michels et al. · New England Journal of Medicine · 2006 · 3.5K citations

, , +13

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

David M. Brown, Mark Michels, Peter K. Kaiser et al. · Ophthalmology · 2008 · 1.3K citations

, , +15

An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration

Anne E. Fung, Geeta A. Lalwani, Philip J. Rosenfeld et al. · American Journal of Ophthalmology · 2007 · 972 citations

, , +12

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

Carl D. Regillo, David M. Brown, Prema Abraham et al. · American Journal of Ophthalmology · 2008 · 862 citations

, , +10